Henan Cancer Hospital

This study will observe about 20 adults with a type of blood cancer called diffuse large B-cell lymphoma that did not respond to or came back quickly after first treatment. Researchers will track how well the drug glofitamab works when given as part of routine care, either alone …

This study tests a daily oral drug called lisaftoclax in 75 adults with slow-growing lymphomas (CLL, WM, or MZL) who cannot take or have stopped responding to standard treatments. The goal is to see if the drug is safe and can shrink or control the cancer. Treatment continues as …

This phase 3 trial tests whether the drug toripalimab, given after surgery, can help prevent esophageal cancer from returning in high-risk patients. About 435 people who had chemotherapy and immunotherapy before surgery will either receive toripalimab or be watched closely. The g…

This study tests a new drug, trastuzumab-rezetecan, against an approved one, T-DXd, in women with early or locally advanced HER2-positive breast cancer. About 68 participants will get one of the two drugs before surgery to see which leads to more tumor disappearance. The goal is …

This study tests a three-part treatment for people with liver cancer that has spread into a major liver blood vessel. Participants will receive radiation therapy plus two drugs (tislelizumab and anlotinib) to shrink tumors and control the disease. The goal is to see how many pati…

This study tests whether adding the drug adebrelimab after standard chemoradiotherapy can help keep limited-stage small cell lung cancer from coming back or spreading. About 200 adults with untreated, limited-stage disease will receive either standard treatment alone or standard …

This study tests whether adding the immunotherapy drug toripalimab to standard chemotherapy before surgery can improve outcomes for people with triple-negative breast cancer. About 216 participants will receive either toripalimab plus one of two chemotherapy combinations. The mai…

This study looks at how well three different drug combinations (BR, R2, and OR2) work as first treatment for people with a slow-growing blood cancer called marginal zone lymphoma. About 131 adults will take part. The goal is to see which treatment best controls the cancer and has…

This study tests whether a combination of two anti-nausea drugs (rolapitant and palonosetron) can prevent vomiting and nausea in lung cancer patients undergoing chemoradiotherapy. About 238 adults with lung cancer will receive the drug combo and be monitored for 6 weeks. The goal…

This study aims to develop an artificial intelligence (AI) system that helps doctors choose the best treatment for each person with esophageal cancer. Researchers will collect medical images and tissue samples from 7,000 patients to train the AI to predict how well a treatment wi…

This study looks at whether the drug anlotinib can still help people with advanced lung cancer even after it has stopped working. Researchers will review medical records from 350 patients with non-small cell or small cell lung cancer. The goal is to see if continuing anlotinib in…